Charles Schwab Investment Management Inc. Has $553,000 Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Charles Schwab Investment Management Inc. lifted its position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 23.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 74,427 shares of the company’s stock after purchasing an additional 13,922 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Lifecore Biomedical were worth $553,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. ARS Investment Partners LLC bought a new stake in Lifecore Biomedical in the fourth quarter valued at approximately $74,000. Public Employees Retirement System of Ohio acquired a new position in shares of Lifecore Biomedical in the 3rd quarter valued at $119,000. Barclays PLC increased its position in shares of Lifecore Biomedical by 301.7% in the 3rd quarter. Barclays PLC now owns 29,944 shares of the company’s stock valued at $147,000 after buying an additional 22,489 shares in the last quarter. Jane Street Group LLC increased its position in shares of Lifecore Biomedical by 101.7% in the 3rd quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock valued at $179,000 after buying an additional 18,277 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its stake in Lifecore Biomedical by 61.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 27,184 shares of the company’s stock worth $202,000 after buying an additional 10,320 shares during the period. Institutional investors own 83.36% of the company’s stock.

Analyst Ratings Changes

Separately, Stephens restated an “equal weight” rating and issued a $6.00 price target on shares of Lifecore Biomedical in a report on Friday, January 3rd.

Insider Activity

In other news, CEO Paul Josephs acquired 17,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The stock was acquired at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the chief executive officer now owns 559,717 shares in the company, valued at $3,212,775.58. This represents a 3.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 32.20% of the company’s stock.

Lifecore Biomedical Stock Performance

Shares of LFCR stock opened at $7.04 on Tuesday. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $7.99. The company’s 50 day moving average price is $6.15 and its two-hundred day moving average price is $6.22. The company has a market capitalization of $260.66 million, a P/E ratio of -12.57 and a beta of 0.96.

Lifecore Biomedical (NASDAQ:LFCR) last issued its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. On average, analysts expect that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.